John C Marston1, Gregory D Kennedy2, Suzanne E Lapi3, Yolanda E Hartman4, Morgan T Richardson5, Himani M Modi5, Jason M Warram6. 1. Department of Surgery, University of Alabama School of Medicine, Birmingham, Alabama; Department of Surgery, Louisiana State University Health Science Center, Baton Rouge, Louisiana. 2. Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama. 3. Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama. 4. Department of Otolaryngology, University of Alabama at Birminghamz, Birmingham, Alabama. 5. Department of Otolaryngology, University of Alabama at Birmingham, Birmingham, Alabama. 6. Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Otolaryngology, University of Alabama at Birminghamz, Birmingham, Alabama; Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, Alabama. Electronic address: mojack@uab.edu.
Abstract
BACKGROUND: Fluorescence-guided surgery (FGS) is a rapidly advancing field that may improve outcomes in several cancer types. Although screening has decreased colorectal cancer (CRC) mortality, it remains a common and often fatal malignancy. In this study, we sought to identify an optical imaging agent for the application of FGS technology to CRC. METHODS: We compared a panitumumab-IRDye800CW conjugate to an IgG-IRDye800CW isotype control. Mice were implanted with one of three CRC cell lines (LS174T, Colo205, and SW948) and imaged with open- and closed-filed fluorescence imaging systems. Fluorescent contrast was quantified by calculating the ratio between tumor and background fluorescence. After 10 d, the mice were sacrificed, and their tumors stained for microscopic imaging. RESULTS: Panitumumab-IRDye800CW produced significantly greater (P < 0.05) fluorescent contrast in all three cell lines. Average tumor to background ratio was 6.00 versus 2.60 for LS174T, 5.78 versus 2.52 for Colo205, and 4.31 versus 1.70 for SW948. A 1-mg tumor fragment produced significantly greater fluorescent contrast in the Colo205 and SW948 cell lines in the panitumumab-IRDye800CW group. Western blotting for epidermal growth factor receptor (EGFR) and a semiquantitative analysis of EGFR expression noted strong expression in all three cell lines; however, EGFR expression did not directly correlate to tumor to background ratio. CONCLUSIONS: Panitumumab-IRDye800CW produces significantly greater fluorescent contrast than IgG-IRDye800CW in a murine model of CRC and is a suitable agent for the application of FGS technology to CRC.
BACKGROUND: Fluorescence-guided surgery (FGS) is a rapidly advancing field that may improve outcomes in several cancer types. Although screening has decreased colorectal cancer (CRC) mortality, it remains a common and often fatal malignancy. In this study, we sought to identify an optical imaging agent for the application of FGS technology to CRC. METHODS: We compared a panitumumab-IRDye800CW conjugate to an IgG-IRDye800CW isotype control. Mice were implanted with one of three CRC cell lines (LS174T, Colo205, and SW948) and imaged with open- and closed-filed fluorescence imaging systems. Fluorescent contrast was quantified by calculating the ratio between tumor and background fluorescence. After 10 d, the mice were sacrificed, and their tumors stained for microscopic imaging. RESULTS:Panitumumab-IRDye800CW produced significantly greater (P < 0.05) fluorescent contrast in all three cell lines. Average tumor to background ratio was 6.00 versus 2.60 for LS174T, 5.78 versus 2.52 for Colo205, and 4.31 versus 1.70 for SW948. A 1-mg tumor fragment produced significantly greater fluorescent contrast in the Colo205 and SW948 cell lines in the panitumumab-IRDye800CW group. Western blotting for epidermal growth factor receptor (EGFR) and a semiquantitative analysis of EGFR expression noted strong expression in all three cell lines; however, EGFR expression did not directly correlate to tumor to background ratio. CONCLUSIONS:Panitumumab-IRDye800CW produces significantly greater fluorescent contrast than IgG-IRDye800CW in a murine model of CRC and is a suitable agent for the application of FGS technology to CRC.
Authors: Kiranya E Tipirneni; Jason M Warram; Lindsay S Moore; Andrew C Prince; Esther de Boer; Aditi H Jani; Irene L Wapnir; Joseph C Liao; Michael Bouvet; Nicole K Behnke; Mary T Hawn; George A Poultsides; Alexander L Vahrmeijer; William R Carroll; Kurt R Zinn; Eben Rosenthal Journal: Ann Surg Date: 2017-07 Impact factor: 12.969
Authors: Leonora S F Boogerd; Charlotte E S Hoogstins; Dennis P Schaap; Miranda Kusters; Henricus J M Handgraaf; Maxime J M van der Valk; Denise E Hilling; Fabian A Holman; Koen C M J Peeters; J Sven D Mieog; Cornelis J H van de Velde; Arantza Farina-Sarasqueta; Ineke van Lijnschoten; Bérénice Framery; André Pèlegrin; Marian Gutowski; Simon W Nienhuijs; Ignace H J T de Hingh; Grard A P Nieuwenhuijzen; Harm J T Rutten; Francoise Cailler; Jacobus Burggraaf; Alexander L Vahrmeijer Journal: Lancet Gastroenterol Hepatol Date: 2018-01-30
Authors: E F Dunn; M Iida; R A Myers; D A Campbell; K A Hintz; E A Armstrong; C Li; D L Wheeler Journal: Oncogene Date: 2010-10-18 Impact factor: 9.867
Authors: Abraham S Moses; Ananiya A Demessie; Olena Taratula; Tetiana Korzun; Ov D Slayden; Oleh Taratula Journal: Small Date: 2021-01-25 Impact factor: 13.281
Authors: Rahul Pal; Marisa E Hom; Nynke S van den Berg; Thinzar M Lwin; Yu-Jin Lee; Andrey Prilutskiy; William Faquin; Eric Yang; Srinivas V Saladi; Mark A Varvares; Eben L Rosenthal; Anand T N Kumar Journal: Clin Cancer Res Date: 2022-06-01 Impact factor: 13.801
Authors: Feredun Azari; Gregory Kennedy; Elizabeth Bernstein; Constantinos Hadjipanayis; Alexander Vahrmeijer; Barbara Smith; Eben Rosenthal; Baran Sumer; Jie Tian; Eric Henderson; Amy Lee; Quyen Nguyen; Summer Gibbs; Brian Pogue; Daniel Orringer; Cleopatra Charalampaki; Linda Martin; Janos Tanyi; Major Lee; John Y Lee; Sunil Singhal Journal: J Biomed Opt Date: 2021-05 Impact factor: 3.170
Authors: Jacqueline Pei; Georgina Juniper; Nynke S van den Berg; Naoki Nisho; Trevor Broadt; Anthony R Welch; Grace S Yi; Roan C Raymundo; Stefania U Chirita; Guolan Lu; Giri Krishnan; Yu-Jin Lee; Shrey Kapoor; Quan Zhou; A Dimitrios Colevas; Natalie S Lui; George A Poultsides; Gordon Li; Kurt R Zinn; Eben L Rosenthal Journal: Mol Imaging Biol Date: 2020-09-03 Impact factor: 3.484
Authors: Thinzar M Lwin; Michael A Turner; Siamak Amirfakhri; Hiroto Nishino; Robert M Hoffman; Michael Bouvet Journal: Cells Date: 2022-01-12 Impact factor: 6.600